• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ATLAS trial: Duration of adjuvant tamoxifen in ER-positive breast cancer [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
April 22, 2014
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Among women with early ER-positive breast cancer, continuing adjuvant tamoxifen for 10 years versus stopping at 5 years after diagnosis significantly reduced breast cancer recurrence, breast cancer mortality, and overall mortality 

2. Patients treated with adjuvant tamoxifen for 10 years had significantly higher risk of endometrial cancer and pulmonary embolism

Original Date of Publication: March 9, 2013

Study Rundown: In women with estrogen receptor (ER)-positive breast cancer, previous trials had demonstrated that treatment with adjuvant tamoxifen for 5 years significantly reduced the risk of recurrence both during the treatment time and for 10 years after. During this 15-year period, mortality from breast cancer was also significantly reduced. Tamoxifen treatment, however, is linked with significantly increased risk of certain side effects, including endometrial cancer and thromboembolic disease. The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial compared the effects of 10 years of adjuvant tamoxifen treatment with 5 years of adjuvant tamoxifen treatment on outcomes in patients with ER-positive breast cancer. Over the duration of follow up, 10-year treatment significantly reduced breast cancer recurrence (RR 0.84; 95%CI 0.76-0.94), breast cancer mortality (RR 0.83; 95%CI 0.72-0.96), and overall mortality (RR 0.87; 95%CI 0.78-0.97) compared to the standard 5-year course of tamoxifen. However, this increased benefit came at the expense of significantly increased rates of endometrial cancer and pulmonary embolism. The study remains ongoing and future data will help elucidate the longer-term effects of prolonged tamoxifen treatment in patients with early ER-positive breast cancer.

Click to read the study in The Lancet

In-Depth [randomized, controlled study]: This multinational study included 12,894 women with early breast cancer, 6,454 of whom were randomized to continue tamoxifen for 10 years (i.e., the intervention group) after diagnosis and 6,440 of whom were randomized to stop tamoxifen use at 5 years (i.e., the control group). While all 12,894 were included in the analysis for side effects, only women with ER-positive disease were included in the main analysis for breast cancer recurrence and mortality – a total of 6,846 women. Patients were eligible for inclusion if they had early breast cancer (i.e., completely resectable disease), they had subsequently received tamoxifen and were still on it (or had stopped in the past year and could resume treatment quickly), they were clinically free of disease (i.e., local recurrence resected, no distant recurrence), follow-up was practicable, and there was uncertainty between the patient and her physician regarding whether to continue tamoxifen treatment. There were no restrictions based on patient age, the type of initial surgery or histology, hormone receptor status, nodal status, or other treatments. Patients were not eligible if they had any contraindications to continuing tamoxifen (e.g., pregnancy, breastfeeding, retinopathy, endometrial hyperplasia).

RELATED REPORTS

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Religious-based interventions improve illness perception in breast cancer patients

Wellness Check: Spirituality

In women with ER-positive disease, continuing tamoxifen treatment for 10 years significantly reduced the risk of breast cancer recurrence (RR 0.84; 95%CI 0.76-0.94), breast cancer mortality (RR 0.83; 95%CI 0.72-0.96), and overall mortality (RR 0.87; 95%CI 0.78-0.97) when compared to 5 years of treatment. Notably, during years 5-14 after diagnosis, the absolute recurrence reduction was 3.7% with extended tamoxifen treatment (21.4% vs. 25.1%). The relative risk of pulmonary embolus (RR 1.87; 95% CI 1.13-3.07) and endometrial cancer (RR 1.74; 95%CI 1.30-2.34) were significantly higher in women who continued tamoxifen compared to the control group, while the risk of ischemic heart disease was significantly reduced (RR 0.76; 95%CI 0.60-0.95).

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Breast Cancertamoxifen
Previous Post

2 Minute Medicine Rewind April 14 – April 20, 2014

Next Post

Celiac disease more prevalent in children with irritable bowel syndrome

RelatedReports

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Early palliative care may improve survival in advanced cancer
Wellness

Wellness Check: Spirituality

January 5, 2023
Oncology

Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention

October 31, 2022
Next Post
Celiac disease more prevalent in children with irritable bowel syndrome

Celiac disease more prevalent in children with irritable bowel syndrome

Idiopathic intracranial hypertension: Key signs and symptoms characterized

Idiopathic intracranial hypertension: Key signs and symptoms characterized

Patient transfers to trauma centers often unnecessary

Ambulances equipped for thrombolysis allow for more rapid stroke treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options